Lysogene Is A Clinical Stage Biotechnology Company Based In Neuilly Sur Seinefrancefocused On Gene Therapy For Rare Genetic Disorders Affecting The Central Nervous Systemparticularly In Childrenfounded In 2009 And Publicly Listed On Euronext Paris Since 2017Lysogene Aims To Meet Unmet Medical Needs In Neurodegenerative Lysosomal Storage Disorders And Other Cns Diseases The Company Operates A Clinical Research Center That Conducts Pre Clinical And Clinical Development Programs For Gene Therapiesthis Includes Efficacy And Toxicology Studies In Animal Modelsas Well As Regulatory And Manufacturing Development Supportlysogene S Pipeline Features Lys Saf302A Gene Therapy In Phase Ii Iii Trials For Mucopolysaccharidosis Type Iiiaand Lys Gm101A Phase I Ii Candidate For Gm1 Gangliosidosisadditionallythe Company Is Developing Pre Clinical Programs For Gaucher Disease And Fragile X Syndrome Through Various Partnershipslysogene Collaborates With Academic Institutions And Patient Organizations To Align Its Research With Patient Needs And Has Received Designations From The Fda To Support Its Therapies
No conferences found for this company.
| Company Name | Lysogene Sa |
| Country |
France
|
| Address | N/A |
| Telephone | N/A |
| N/A |
